Telix Pharmaceuticals H1 2024 Results Presentation

Telix Pharmaceuticals' H1 2024 interim results presentation delivered on 22 August 2024. The presentation covers financial and operational achievements for the first half of 2024, including updates on the company's lead product Illuccix® for prostate cancer imaging, which has received regulatory approvals in Australia, the United States, and Canada.